newsfilter
← Latest News
GlobeNewswire·

Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results

Generated $196.8 million in 3Q 2024 revenues, including $176.6 million in U.S. net product salesGrew SYFOVRE® (pegcetacoplan injection) demand by 7% quarter-over-quarter, with U.S. net product revenue of $152.0